Clinicopathological significance of APC mutation in patient with colorectal cancer.

IF 2.5 3区医学 Q3 ONCOLOGY Oncology Pub Date : 2025-03-13 DOI:10.1159/000545255

Kyoung Min Kim, Woo Sung Moon, Gi Won Ha, Ho Sung Park, Kyu Yun Jang, Min Ro Lee, Myoung Ja Chung, Ae Ri Ahn

{"title":"Clinicopathological significance of APC mutation in patient with colorectal cancer.","authors":"Kyoung Min Kim, Woo Sung Moon, Gi Won Ha, Ho Sung Park, Kyu Yun Jang, Min Ro Lee, Myoung Ja Chung, Ae Ri Ahn","doi":"10.1159/000545255","DOIUrl":null,"url":null,"abstract":"Introduction: In colorectal cancer (CRC), the prognostic significance of Adenomatous polyposis coli (APC) mutations remains controversial. We aimed to investigate the effect of APC mutations on the prognosis of patients with CRC and to elucidate the clinicopathological features associated with these mutations.Methods: Formalin-fixed, paraffin-embedded CRC specimens were tested for APC mutations using targeted next-generation sequencing, mismatch repair (MMR) deficiency was evaluated using immunohistochemical staining. Clinicopathological features were obtained from medical records and through a review of hematoxylin and eosin slides.Results: APC mutations and MMR deficiencies were detected in 72.8% and 8.9% of the patients with CRC, respectively. APC mutations were significantly correlated with male sex (P = 0.046) and left colon cancer (P < 0.001). They were inversely correlated with age (P = 0.020), serum 19-9 elevation (P = 0.047), distant metastasis (P = 0.005) and MMR deficiency (P < 0001). In univariate analysis, APC mutations correlated with longer overall survival in patients with CRC.Conclusions: APC mutations are associated with favorable prognostic factors and longer overall survival. Further investigation is needed to understand the mechanisms of association between APC mutations to favorable cancer prognosis and their correlation MMR protein expression.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-17"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545255","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In colorectal cancer (CRC), the prognostic significance of Adenomatous polyposis coli (APC) mutations remains controversial. We aimed to investigate the effect of APC mutations on the prognosis of patients with CRC and to elucidate the clinicopathological features associated with these mutations.

Methods: Formalin-fixed, paraffin-embedded CRC specimens were tested for APC mutations using targeted next-generation sequencing, mismatch repair (MMR) deficiency was evaluated using immunohistochemical staining. Clinicopathological features were obtained from medical records and through a review of hematoxylin and eosin slides.

Results: APC mutations and MMR deficiencies were detected in 72.8% and 8.9% of the patients with CRC, respectively. APC mutations were significantly correlated with male sex (P = 0.046) and left colon cancer (P < 0.001). They were inversely correlated with age (P = 0.020), serum 19-9 elevation (P = 0.047), distant metastasis (P = 0.005) and MMR deficiency (P < 0001). In univariate analysis, APC mutations correlated with longer overall survival in patients with CRC.

Conclusions: APC mutations are associated with favorable prognostic factors and longer overall survival. Further investigation is needed to understand the mechanisms of association between APC mutations to favorable cancer prognosis and their correlation MMR protein expression.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.